Clearside Biomedical (NASDAQ:CLSD) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Clearside Biomedical (NASDAQ:CLSD) released its quarterly earnings data on Sunday. The company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.03), MarketWatch Earnings reports. Clearside Biomedical had a negative net margin of 144.47% and a negative return on equity of 153.41%.

Clearside Biomedical stock traded up $0.06 during midday trading on Tuesday, hitting $2.43. 1,635 shares of the stock were exchanged, compared to its average volume of 564,709. Clearside Biomedical has a 52-week low of $1.25 and a 52-week high of $4.53. The stock has a market capitalization of $139.92 million, a price-to-earnings ratio of -7.53 and a beta of 1.42. The business’s 50-day moving average price is $2.69 and its 200-day moving average price is $2.73. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.05.

CLSD has been the subject of a number of recent analyst reports. Wedbush reissued a “buy” rating and set a $6.00 target price on shares of Clearside Biomedical in a research report on Tuesday. Zacks Investment Research raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 12th. Finally, Roth Capital upped their price objective on shares of Clearside Biomedical from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $6.00.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.

Recommended Story: Arbitrage

Earnings History for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with's FREE daily email newsletter.